Aminophylline

Overview

Aminophylline is a parenteral methylxanthine bronchodilator that serves as an injectable form of theophylline and is used in dogs and cats for its airway smooth muscle–relaxing effects. It is most commonly employed as an adjunctive therapy in the management of respiratory diseases associated with bronchoconstriction and chronic cough.

In small animals, aminophylline is primarily indicated for conditions such as tracheitis, chronic bronchitis, airway collapse, and other respiratory disorders where bronchodilation and improved airflow are desired. It may also be beneficial in select patients with congestive heart failure when respiratory disease complicates clinical management.

Compared with oral theophylline, aminophylline allows for rapid achievement of therapeutic plasma concentrations via intravenous administration, making it useful in hospitalized patients or acute settings. However, due to its narrow therapeutic index and potential for significant adverse effects, careful dosing, slow IV administration, and close monitoring are essential.

Mechanism of Action (MOA): Aminophylline inhibits phosphodiesterase enzymes (primarily PDE III and, to a lesser extent, PDE IV), leading to increased intracellular cyclic AMP (cAMP). This results in relaxation of bronchial smooth muscle and bronchodilation. Additional effects include mild central nervous system stimulation, enhanced diaphragmatic contractility, increased mucociliary clearance, and weak positive chronotropic and inotropic cardiac effects. Aminophylline also antagonizes adenosine receptors, which contributes to its bronchodilatory and CNS stimulant actions.

Indications

Aminophylline is used in dogs and cats primarily for its bronchodilatory properties and is most often administered as an adjunctive therapy in respiratory conditions associated with bronchoconstriction and chronic cough. Its use is generally reserved for patients that require parenteral therapy or when rapid onset of action is desired.

• Chronic bronchitis and tracheitis: Used to relieve bronchoconstriction and reduce cough in dogs and cats with inflammatory airway disease.
• Airway collapse: Adjunctive treatment in patients with tracheal or bronchial collapse to improve airflow and decrease coughing episodes.
• Chronic cough of respiratory origin: May be beneficial in animals with persistent cough where bronchospasm contributes to clinical signs.
• Respiratory disease complicating congestive heart failure: Can be used to help relieve cough and bronchoconstriction in selected dogs and cats when cardiac disease is accompanied by airway disease.
• Bradyarrhythmias (selected cases): Occasionally used to manage sick sinus syndrome or other bradyarrhythmias due to its mild positive chronotropic effects.

Although aminophylline and other theophyllines are still used in small animal practice, their clinical application is limited by a narrow therapeutic index and the availability of alternative bronchodilators with wider safety margins. Careful patient selection and monitoring are essential.

Dosage (Reference)

Dog

In dogs, aminophylline is used as a short-acting parenteral bronchodilator. Dogs generally tolerate higher plasma theophylline concentrations than humans, but careful dosing and monitoring are still required due to the drug’s narrow therapeutic index.

Cat

In cats, aminophylline is used cautiously due to increased sensitivity to adverse effects. Lower doses and longer dosing intervals are recommended compared with dogs.

Warnings & Precautions

Aminophylline has a narrow therapeutic index and must be used with caution in dogs and cats. Adverse effects are closely related to serum drug concentrations, and careful patient selection, dose calculation, and monitoring are essential.

• Xanthine hypersensitivity: Contraindicated in dogs and cats with known hypersensitivity to xanthines, including aminophylline, theophylline, caffeine, or theobromine.
• Seizure disorders: Contraindicated in dogs with a history of epileptiform seizures. Use extreme caution in cats or dogs with any seizure predisposition.
• Cardiac disease: Use cautiously in patients with severe cardiac disease or pre-existing arrhythmias, as aminophylline may induce or worsen tachyarrhythmias.
• Hepatic disease: Clearance is significantly reduced in animals with hepatic dysfunction. Dose reduction (up to 50%) may be required to avoid toxicity.
• Congestive heart failure (CHF): Aminophylline clearance may be reduced by approximately 50%; careful dose adjustment and monitoring are recommended.
• Renal disease: Use cautiously in patients with renal impairment, as metabolic and electrolyte disturbances may exacerbate adverse effects.
• Endocrine and systemic disease: Use with caution in animals with hyperthyroidism, severe hypertension, fever, sepsis, or severe hypoxia, as drug clearance may be altered.
• Neonatal and geriatric patients: Reduced drug clearance may occur, increasing the risk of toxicity; start at the low end of the dosing range.
• IM administration: Causes intense local pain and is generally discouraged; IV administration is preferred when parenteral therapy is required.
• IV administration: Rapid or undiluted IV injection can cause hypotension, arrhythmias, tremors, and acute respiratory compromise; administer slowly or as a controlled infusion.
• Obese patients: Due to low lipid solubility, doses should be calculated based on lean body weight, not total body weight.

Drug Interactions

Aminophylline (theophylline) has numerous clinically important drug interactions in dogs and cats. Many interactions alter serum theophylline concentrations or increase the risk of CNS stimulation and cardiac arrhythmias. Careful dose adjustment and close monitoring are required when aminophylline is used concurrently with other medications.

• Ketamine: Concurrent use may increase the risk of seizures and cardiac arrhythmias; avoid combination when possible.
• Sympathomimetics (e.g., albuterol, ephedrine, isoproterenol, phenylpropanolamine): Additive CNS stimulation and arrhythmias may occur. Toxic synergism is possible, particularly with ephedrine.
• Barbiturates (e.g., phenobarbital): May increase theophylline metabolism and reduce serum concentrations in dogs (effect not documented in cats).
• Fluoroquinolones (e.g., enrofloxacin, ciprofloxacin): Can markedly increase theophylline concentrations; consider reducing the aminophylline dose by 30% or extending the dosing interval and monitor for toxicity.
• Macrolide antibiotics (e.g., erythromycin, clarithromycin): May increase theophylline serum concentrations and the risk of adverse effects.
• Chloramphenicol: May significantly increase theophylline concentrations; dose reduction or interval extension is recommended.
• Cimetidine: Can inhibit theophylline metabolism and increase serum concentrations.
• Calcium channel blockers (e.g., diltiazem, verapamil): May increase theophylline concentrations and enhance cardiovascular effects.
• Beta-blockers, non-selective (e.g., propranolol): May increase theophylline concentrations and blunt compensatory cardiovascular responses.
• Corticosteroids (e.g., dexamethasone, prednisolone): May increase theophylline serum concentrations; monitor for signs of toxicity.
• Selective serotonin reuptake inhibitors (e.g., fluoxetine): May reduce theophylline clearance and increase plasma concentrations.
• Activated charcoal: Decreases theophylline absorption when administered orally.
• Rifampin: May decrease theophylline concentrations by inducing hepatic metabolism.
• Thyroid hormones (in hypothyroid patients): May increase theophylline clearance as metabolic rate normalizes.
• Benzodiazepines (e.g., diazepam, midazolam): Theophylline may reduce the sedative effects of benzodiazepines.
• Lithium: Theophylline may decrease lithium serum concentrations and efficacy.
• Propofol: Theophylline may reduce anesthetic effects, potentially increasing dose requirements.

Side Effects & Overdose

Side Effects

Adverse effects of aminophylline in dogs and cats are dose-dependent and closely related to serum theophylline concentrations. Many clinical signs indicate excessive plasma levels and may precede serious toxicity. Dogs generally tolerate higher concentrations than humans, but careful monitoring is still required.

• Gastrointestinal effects: Nausea, vomiting, diarrhea, increased gastric acid secretion, and anorexia are common, especially during initiation of therapy.
• Central nervous system stimulation: Restlessness, agitation, insomnia, tremors, and excitement may occur; these signs are usually transient but may worsen with higher doses.
• Cardiovascular effects: Tachycardia and increased heart rate may occur, particularly at plasma concentrations above 30 µg/mL in dogs.
• Polyuria and polydipsia: Related to the mild diuretic effects of methylxanthines.
• Local reactions: Intramuscular administration causes intense pain and irritation and is generally avoided.
• Transient effects during initiation: Mild CNS stimulation or GI upset may occur when therapy is started and often resolves spontaneously.

Overdose

Toxicity associated with aminophylline and theophylline primarily affects the cardiovascular and central nervous systems. In humans, toxicity typically occurs at serum concentrations greater than 20 µg/mL, while dogs and cats may tolerate higher concentrations; however, life-threatening effects can still occur with overdose.

• Cardiac toxicity: Tachycardia, serious arrhythmias, hypotension, and cardiovascular collapse, particularly with rapid IV administration.
• Neurologic toxicity: Severe agitation, tremors, hyperthermia, and seizures, which represent the most life-threatening complications.
• Metabolic disturbances: Hypokalemia and acid–base abnormalities may be present in severe overdoses.
• Management: Treatment is supportive and includes continuous ECG monitoring, correction of fluid and electrolyte abnormalities, and temperature control.
• GI decontamination: Activated charcoal may be used to reduce further absorption and is more effective than inducing emesis.
• Seizure control: IV benzodiazepines (e.g., diazepam or midazolam) are recommended if seizures occur.
• Arrhythmia management: Beta-blockers (e.g., propranolol) may be considered for life-threatening tachycardia.
• Advanced therapy: Hemodialysis can enhance theophylline removal in severe cases when available.

Key Notes

Practical clinical pearls to optimize the safe and effective use of aminophylline in dogs and cats, focusing on points not covered elsewhere in this monograph.

• Adjunctive role: Aminophylline is best used as an adjunct bronchodilator rather than sole therapy, especially in chronic lower airway disease.
• Parenteral to oral transition: Injectable aminophylline is primarily for short-term use; transition to oral theophylline is recommended as soon as the patient is stable.
• Dosing based on lean body weight: Due to low lipid solubility and volume of distribution, dosing obese patients based on lean body weight reduces overdose risk.
• Slow IV administration: IV doses should always be diluted and administered slowly or as an infusion to minimize cardiovascular and neurologic complications.
• High interpatient variability: Response and tolerance vary widely between individual dogs and cats; dose adjustments should be guided by clinical response.
• Monitoring value: Measuring serum theophylline concentrations is particularly useful in patients with poor response, adverse effects, or concurrent disease.
• Use with cardiac disease: In patients with concurrent congestive heart failure and respiratory disease, aminophylline may improve cough but requires careful cardiac monitoring.
• Avoid IM route: Intramuscular administration is discouraged due to significant local pain and tissue irritation.
• Client education: Owners should be informed that restlessness, GI upset, or sleep disturbances may signal excessive dosing and warrant veterinary re-evaluation.